Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

BACKGROUND: We previously found that administration of an interleukin 2/diphtheria toxin conjugate (DAB/IL2; Denileukin Diftitox; ONTAK) to stage IV melanoma patients depleted CD4(+)CD25(HI)Foxp3(+ )regulatory T cells and expanded melanoma-specific CD8(+ )T cells. The goal of this study was to asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Telang, Sucheta, Rasku, Mary Ann, Clem, Amy L, Carter, Karen, Klarer, Alden C, Badger, Wesley R, Milam, Rebecca A, Rai, Shesh N, Pan, Jianmin, Gragg, Hana, Clem, Brian F, McMasters, Kelly M, Miller, Donald M, Chesney, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293785/
https://www.ncbi.nlm.nih.gov/pubmed/22165955
http://dx.doi.org/10.1186/1471-2407-11-515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293785/
https://www.ncbi.nlm.nih.gov/pubmed/22165955
http://dx.doi.org/10.1186/1471-2407-11-515

Ejemplares similares